Rheumatoid arthritis and its impact on ulceration and healing

Rheumatoid arthritis (RA) is a systemic autoimmune condition that has episodes of activity along with periods of remission during which signs and symptoms of the disease are absent. Approximately 1% of the UK population has RA, which equates to over 400,000 people (National Rheumatoid Arthritis Society [NRAS], 2014). RA is thought to have a genetic component and is also influenced by environmental factors, such as viruses or smoking (NRAS, 2014). The systemic effects of the disease can involve the heart, lungs and eyes (National Institute for Heath and Care Excellence [NICE], 2018). The prevalence of RA rises with age, although it can occur in a younger population; it is referred to as early-onset RA if it starts from age 14 years (NRAS, 2014). The condition is more prevalent in women (NICE, 2018).

RA has historically been linked to the occurrence of wounds and a delay in wound healing. Garner et al (1973) completed a retrospective study investigating the healing potential of 100 patients with RA who were taking corticosteroids for the disease compared to a population without RA or any inflammatory joint disease. They found a significant increase in time to healing in the RA group (P<0.02). Lower-extremity ulcers are a recognised complication of RA (Shanmugmam et al, 2011). Shanmugmam and colleagues (2011) followed patients with RA and lower extremity ulcers for 3 years. In this group, just over 30% of ulcers healed within 2 years, even when in clinical remission. The prevalence of foot ulceration in UK patients with RA has been reported as 3.9% (Firth et al, 2008). In the US, the prevalence is higher than this, reaching 4.37% when all the lower leg ulcers are included (Shanmugmam et al, 2011). A relatively recent study including a small cohort of RA patients with foot ulcers (n=32) found mean time to healing to be 41 days (Siddle et al, 2012).

PATHOPHYSIOLOGY

Tissue viability problems in RA are due to the disease process itself and its consequential effects on activities of daily living. Tissue viability complications are influenced by the severity of the disease and the medication prescribed to control/suppress the disease process (Firth, 2005). The disease itself is a result of increased T-cell activity and pro-inflammatory cytokine production, which if untreated can lead to irreversible joint destruction (Firth, 2011a).

In RA there is symmetrical inflammatory arthritis, which most commonly affects the smaller joints of the hands and feet. However, it is not limited to the hands and feet. More substantial joints, such as those in the wrists and knees, can also be implicated in the disease process (Firth and Siddle, 2009). The inflammation attacks the
Inflammation is not restricted to the joints. Sjögren's Syndrome involves inflammation of the temporomandibular joints in patients with RA which leads to reduced lubrication in the mouth and consequently a problem with chewing food (Firth, 2005). It can also affect the circulatory system, resulting in vasculitis. Cutaneous rheumatoid vasculitis usually affects the small and medium-sized vessels that supply the skin and other organs. It can result in the development of cutaneous ulcers. Trauma due to foot deformity is another cause of ulceration in individuals with RA (Shanmugam et al, 2011).

Although venous leg ulceration is commonly found in individuals with RA, patients may present with leg ulcers of various aetiologies. Following investigation and histological sampling in 20 individuals with RA and leg ulceration, 10 ulcers were found to be multifactorial, 15 were due to venous insufficiency, 11 were vasculitic in origin and four were caused by peripheral arterial disease (Oien et al, 2001).

Neuropathy is a complication of RA in which there is local nerve damage, often due to joint deformity (Firth, 2005). It usually affects both sides of the body and presents with a wide range of symptoms including pain, numbness, a tingling or prickling sensation and muscle weakness (Kaeley et al, 2019).

Activities of daily living are affected by RA because damage to the joints, subsequent loss of mobility and manual dexterity, result in the individual being less able to perform self-care (Firth, 2005).

PSYCHOLOGICAL EFFECTS
As with many chronic illnesses, RA can have a significant impact on a person’s mental health, with reports of anxiety and depression being prevalent in individuals with RA (Firth, 2005). This can be a direct result of pain and fatigue and the limitations RA imposes on activities of daily living. A qualitative study investigating the impact of foot ulceration on health-related quality of life in individuals with RA found ulceration to...
have an addition impact on physical, social and psychological domains, highlighting feelings of hopelessness (Firth et al, 2011).

TREATMENT
A number of medications are used to treat RA. These have various benefits but may result in drawbacks with regards to wound healing. Disease-modifying anti-rheumatic drugs (DMARDs) act on the immune system and slow or stop the radiological progression of RA (NICE, 2018).

DMARDs have revolutionised the management of RA and improved the functional status of patients (Ito et al, 2015). A retrospective review found that DMARDs did not increase the risk of surgical site infection but did delay wound healing in RA patients undergoing elective orthopaedic procedures (Tada et al, 2016).

Corticosteroids are often used to treat RA. They may not be appropriate for patients at high risk of ulceration as they have an adverse impact on the inflammatory and proliferative stages of wound healing as well as wound contracture. In addition to this, individuals on long-term steroid therapy develop paper-thin skin that is susceptible to tears and breaks easily when traumatised (Firth, 2005).

Biological therapies — mainly tumour necrosis factor inhibitors such as infliximab and adalimumab — work by targeting pro-inflammatory cytokines. They have an adverse effect on the immune system, however, placing individuals at a greater risk of developing local, generalised and surgical site infection and delayed wound healing (Firth and Crutchley, 2011; Fitzgerald et al, 2015; Ito et al, 2015).

Methotrexate targets both pro- and anti-inflammatory cytokines. It is often given in combination with biological therapies. Close monitoring is required because liver toxicity can develop in some individuals taking methotrexate (Firth et al, 2008; 2011a).

Drug-induced gastric bleeding in patients with RA can cause anaemia, which will delay the healing process (Firth, 2005).

The prevention and management of ulceration in RA requires a multidisciplinary approach (Firth, 2011b). Preventive medical management includes the monitoring of systemic medication and, when appropriate, screening for vasculitis in other organs of the body and for sepsis. The physiotherapist will be able to help with exercise programmes to improve mobility and functional activity, while the occupational therapist can educate the individual on joint protection (Firth, 2011b). The podiatrist can provide foot screening to monitor for foot deformities and debride callosities if present. Ankle brachial pressure index screening can be problematic and too painful for individuals with RA to tolerate. In this situation, toe brachial pressure readings should be undertaken (Siddle et al, 2012). The podiatrist or orthotist can provide footwear and off-loading equipment to accommodate foot abnormalities if present (Firth, 2005). The nurse can advise patients on how to maintain skin integrity by using emollient therapy. They can also explain how to implement the

Figure 2. Various forms of foot deformity that may occur in patients with rheumatoid arthritis (adapted from Firth, 2005)
International Skin Tear Advisory Panel best practice recommendations for preventing and managing skin tears to patients receiving long-term systemic steroid therapy for RA (Carville, 2014; LeBlanc et al., 2018).

If ulcers require the application of a dressing, the fragility of the patient’s skin needs to be considered. Skin-friendly adhesives should be used and, if necessary, adhesive remover is used to prevent skin trauma on dressing removal. The presence of local infection may be a complication and should be highlighted as a potential problem in the individual’s plan of care. Negative pressure wound therapy (NPWT) can be used for local wound management. Morimoto et al. (2016) developed a NPWT grip tape technique to aid artificial dermis conformability to a circumferential venous leg ulcer in a patient with RA. NPWT has been used successfully with a silver hydrofibre dressing to treat an infected leg ulcer in a RA patient (Bazanlinski et al., 2018).

Patient education is an important part of treatment, especially relating to ulceration and the its prevention (Firth et al., 2012). NICE quality standards recommend that patients with a new presentation of RA be offered educational and self-management activities within 1 month of diagnosis (Ledingham et al., 2017).

CONCLUSION

RA is a systemic autoimmune disease and skin ulceration, mainly of the lower leg and foot, is a recognised complication of the condition. Ulceration can be multifactorial and caused by various means, such as trauma, venous insufficiency, pressure and vasculitis. Individuals have to cope with living with this chronic long-term disease, the need for surgical interventions to treat joint erosion and restrictions on their everyday activities. Consequently, RA and the ulceration that can result from it have a detrimental impact on the individual’s quality of life. Although DMARDs have improved the functional ability of many individuals, they can have a negative impact on the healing process and place the individual at risk of recurrent wound infections (Ito et al., 2015).

Management of the individual with RA and ulceration is multifactorial and involves a multitude of healthcare professionals involved in screening, prevention and management. Local wound management depends on the clinical challenges posed by the ulcer and surrounding skin. There are reports of NPWT being used to treat these individuals. RA and ulceration are a complex set of circumstances that are clinically very challenging. As yet there are no optimal solutions.

REFERENCES


Wounds UK | Vol 15 | No 4 | 2019